BackCuranex PharmaceuticalsCommon Stock Overview

Curanex PharmaceuticalsCommon Stock Other Current Assets

Latest other current assets for CURX: $1.9M.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$1.85M
207.82% YoYΔ $1.25M vs prior year quarter

Peer average / median

Loading

Curanex PharmaceuticalsCommon Stock Other Current Assets History

Loading

Curanex PharmaceuticalsCommon Stock vs. peers: Other Current Assets Comparison

Loading

Curanex PharmaceuticalsCommon Stock Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Curanex PharmaceuticalsCommon Stock (CURX) FAQ

Curanex PharmaceuticalsCommon Stock posts a other current assets of $1.9M as of June 2026. That compares with $600K in the prior-year period — up 207.8% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Curanex PharmaceuticalsCommon Stock's other current assets was $600K. The latest reading is $1.9M — a 207.8% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Other Current Assets is one piece of Curanex PharmaceuticalsCommon Stock's financial statement story. At $1.9M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CURX's other current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Curanex PharmaceuticalsCommon Stock's other metric pages and overview cover the third.

Judging Curanex PharmaceuticalsCommon Stock against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in other current assets easier to interpret. Start with $1.9M here, then scan peer and history charts to see if the gap is persistent.